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Presently, neurodegenerative diseases and cancer are the most clinically problematic
age-related diseases worldwide. Although being distinct disorders, their developments
share common cellular mechanisms. Oncogenesis and neurodegeneration arise from
the deregulation of signaling pathways, as a consequence of the resulting imbalance
in cellular homeostasis. The epidermal growth factor receptor (EGFR) belongs to an
important cellular signaling pathway, which regulates proliferation, differentiation, cell cycle
and migration. As transcriptional targets of EGFR, the microRNAs-221/222 (miR-221/222)
are important expression regulators. Dysfunctions in their networks are associated with
cellular disruptions. The transcriptional activation of these microRNAs (miRNAs) seems
to be involved in cell cycle, apoptosis, metastization, and in the acquisition of resistance
to therapies. The up-regulation of miR-221/222 is associated with increased expression
levels of matrix metalloproteinases (MMPs) and repression of cell cycle inhibitors, which
are key molecules in oncogenesis and neurodegeneration processes. The interaction loop
between proliferative signaling pathways and miRNA expression could reveal new targets
for controlling the molecular behavior of age-related diseases.
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INTRODUCTION
Presently, neurodegenerative diseases (NDs) and cancer are the
two most clinically problematic age-related diseases with a rel-
evant impact on public health worldwide, with incidence rates
growing over the years alongside with the aging of the populations
(Du and Pertsemlidis, 2011).
Cancer and ND are a complex group of different diseases, with
different etiologies, treatments and prognosis. Although ND and
cancer are two distinct clinical disorders, where the high cellular
division rate of cancer cells contrast with the low cellular divisions
observed in neurons, it has been hypothesized that oncogenesis
and neurodegeneration may share common cellular mechanisms.
One of those mechanisms is the deregulation of proliferative
signaling pathways (Morris et al., 2010).
Several environmental factors, like viral infections and expo-
sure to certain toxic compounds, might be involved in oncoge-
nesis and neurodegeneration initiation. These factors could be
responsible for mutations in multiple genes involved in cell cycle
progression, DNA repair, and cell proliferation leading to cellular
deregulation.
Cells usually have a tight control over their signaling path-
ways, resulting in precise gene expression. Deregulation of these
pathways can have dramatic effects on the expression of target
downstream genes and protein formation, resulting in cellular
homeostasis imbalance. Cellular homeostasis is normally regu-
lated by the concerted actions of both mitogenic growth signals
and anti-proliferative signals. In fact, some authors suggest that
aberrant growth and differentiation are caused by an inappro-
priate cellular microenvironment (Long et al., 2005). Functional
genetic polymorphisms, with the ability to modulate cellular
microenvironment, could influence the carcinogenic processes.
For instance, changes in circulating levels of epidermal growth
factor (EGF) and transforming growth factor beta 1 (TGFβ1), due
to functional genetic variants, could influence the risk to develop
prostate and lung cancer, respectively (Teixeira et al., 2008, 2011).
Several studies showed that these genetic alterations, with an
impact on the cellular microenvironment, could also be involved
in the acquisition of resistant phenotypes to different antineo-
plastic therapies. Moreover, changes in the proliferative epidermal
growth factor receptor (EGFR) pathway influence the response to
androgen deprivation therapy (in advanced cases of the prostate
cancer) and can modulate cancer progression in different can-
cer models (Wang et al., 2007; Teixeira et al., 2009; Costa et al.,
2011).
Deregulation of signaling pathways is a hallmark which often
occurs in malignant diseases. The EGFR transactivation stimu-
lates a network of cytoplasmatic transduction molecules, lead-
ing to a transcriptional activation and consequent modulation
of a wide variety of cellular functions, including cell prolifera-
tion, migration, adhesion, and differentiation. The up-regulation
of this pathway has been found in several tumors, including
non–small cell lung cancer (NSCLC), head and neck carci-
noma, gliomas, and colorectal carcinoma (Chung et al., 2006;
Coldren et al., 2006). This suggests that EGFR overexpression is
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an important event in cancer development and progression. The
activation of the EGFR pathway is also responsible for the tran-
scriptional activation of specific microRNAs (miRNAs), which are
a new class of biomarkers involved in gene regulation (Shah and
Calin, 2011; Stinson et al., 2011).
MiRNAs are a family of endogenous and short non-coding
RNAs (20–25 nucleotides) that exert their effect by negatively
regulating gene expression through one of the two mecha-
nisms: mRNA degradation or translational suppression. MiRNAs
play an important role in different biological processes, such
as cell proliferation, cell growth, apoptosis, signal transduc-
tion, cell cycle, and neurogenesis (Shah et al., 2009; Shah
and Calin, 2011). Changes in miRNA regulation networks can
cause disruptions of the normal cellular activity leading to
disease development. The tight control necessary for cellu-
lar homeostasis, evolutionarily provided the cell with mecha-
nisms for precise gene regulation. Recently, miRNAs emerged
as an important class of gene expression regulators involved
in cancer and neurodegenerative pathologies (Cooper et al.,
2009).
The widespread deregulation ofmiRNAs in all types of tumors,
may allow us to consider that their expression signature is a use-
ful diagnostic and prognostic tool. MiRNA expression analysis
has confirmed that specific miRNAs show differential expres-
sion patterns between normal and tumor tissues. For example,
miR-10b is specifically overexpressed in metastatic breast can-
cer, but downregulated in primary breast tumors (Iorio et al.,
2005). In the process of neuron deterioration, studies performed
by Kim and co-workers showed that alterations in miRNA net-
works of the brain may result in neurodegenerative disorders
(Kim et al., 2007). In addition, Ghelani and co-workers observed
that the deregulation of the expression of specific miRNAs could
be associated with several types of neurodegenerative disorders,
the downregulation of miR-9 and miR-107 were associated with
Alzheimer’s disease (AD), due to their impact on the modula-
tion of insulin resistance and innate immunity pathways (Shioya
et al., 2010; Ghelani et al., 2012; Saito and Saito, 2012). MiRNAs
also demonstrate a unique pattern of regional and subcellular
localization in the brain: for example, miR-221/222 are prefer-
entially found in the hippocampus, while miR-195, miR-497,
and miR-30b are found in the cerebellum (Feng and Feng,
2011).
Several studies have shown an interesting interaction loop
between growth factor activation of the EGFR pathway and the
transcriptional activation of specific miRNAs (Hayashi et al.,
2009; Avraham et al., 2010). Studies performed by Avraham
and co-workers showed that after EGF stimulation, cells ini-
tiated a coordinated transcriptional program of miRNAs and
transcription factors involved in a rapid induction of onco-
genic transcription factors, such as c-FOS, encoded by immedi-
ate early genes (Avraham et al., 2010). Hayashi and co-workers
observed in a fetal murine submandibular salivary grand (SMG)
model (useful in the study of organogenesis, differentiation,
proliferation, and epithelial-mesenchymal interaction) that dif-
ferent miRNA profiles were expressed specifically at different EGF
concentrations in vitro (Hayashi et al., 2009; Avraham et al.,
2010).
The interaction link between proliferative signaling pathways
and miRNA expression profiles involved in oncogenesis and neu-
rodegeneration could reveal interesting molecular targets for the
development of new therapies that would improve the manage-
ment of age-related diseases (Figure 1).
THE ROLE OF THE EGFR SIGNALING PATHWAY IN CANCER
AND NEURODEGENERATIVE DISEASES
EGFR, also known as HER-1 or ErbB-1, is a transmembrane gly-
coprotein with tyrosine kinase activity. This receptor belongs to
the ErbB family of receptors kinases and regulates relevant cel-
lular processes, including proliferation, differentiation, cell cycle
progression, and migration. In addition, EGFR is involved in
the pathogenesis and maintenance of several human cancers of
epithelial origin (Webster et al., 2009).
In a normal tissue, the ligand EGF binds to the EGFR inducing
the dimerization of one or several members of the EGF recep-
tor family (ErbB 1–4). This process activates several tyrosine
kinases, and other downstream signaling molecules, promoting
gene transcription in the cell’s nucleus (Wang et al., 2007).
In cancer cells, EGFR ligand levels are frequently elevated and
EGFR itself is commonly overexpressed (Vicentini et al., 2003).
This overexpression, as well as structural genetic alterations, has
been reported in many malignancies including breast cancer,
prostate cancer, NSCLC, gliomas, and also been associated with
poor prognosis (De Muga et al., 2010). EGFRmutations are more
FIGURE 1 | Cellular microenvironment modulation in aging processes.
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frequently reported in lung cancer, compared with prostate and
colorectal cancer, and very uncommon in head and neck, pan-
creas, esophagus and breast cancers (Lee et al., 2005, 2007; Kwak
et al., 2006; Sharma et al., 2007; Sibilia et al., 2007). However,
other variations, such as single nucleotide polymorphism in the
EGFR gene, can also modulate the microenvironment. For exam-
ple, the G>T transition in the promoter position −260 of EGFR
increases the promoter’s activity (Liu et al., 2005) (Table 1).
Nowadays, EGFR status is a prognostic tool in several cancers,
indicating poor survival, more aggressive behavior, increased risk
of invasion/metastasis, and resistance to antineoplastic therapies
(Press et al., 2008). In fact, this pathway has been proposed to be
involved in hormone-resistant prostate cancer development, as an
alternative proliferative pathway in the absence of androgens dur-
ing androgen deprivation therapy, conferring a poor prognosis to
the patients, with limited therapeutic options (Attar et al., 2009).
The important role of the EGFR signaling pathway in onco-
genesis made it a good candidate for targeted cancer therapy.
Early studies demonstrated that targeting the catalytic domain
of EGFR, using tyrosine kinase inhibitors (TKIs), had an anti-
cancer effect (Fry et al., 1994; Bos et al., 1997). These TKIs inhibit
the growth of cancer cells by inducing cell-cycle arrest and/or
apoptosis. Several anti-EGFR strategies that target different com-
ponents of the EGFR-pathway have been developed in different
cancer models (Amit et al., 2007). However, anti-EGFR thera-
pies are associated with some side-effects, such as skin toxicity,
due to the essential role of EGFR in normal keratinocyte biology.
Nonetheless, some genetic characteristics are associated with a
higher therapeutic benefit (Heist and Christiani, 2009; Dahan
et al., 2011).
Table 1 | Alterations of components of the EGFR signaling pathway in
age-related diseases.
Age-related disease EGF/EGFR signaling pathway
Prostate cancer EGFR overexpressed and moderately
mutated; ligands frequently overexpressed;
EGF/EGFR genetic polymorphisms
Breast cancer EGFR overexpressed and rarely mutated;
EGF/EGFR genetic polymorphisms
Lung cancer EGFR frequently mutated; EGF/EGFR genetic
polymorphisms
Glioma EGFR frequently overexpressed; ligands
overexpressed; EGF/EGFR genetic
polymorphisms
Colorectal cancer EGFR frequently overexpressed and
moderately mutated; ligands overexpressed;
EGF/EGFR genetic polymorphisms
Head and neck cancer EGFR frequently overexpressed and rarely
mutated; EGF/EGFR genetic polymorphisms
Pancreatic cancer EGFR overexpressed and rarely mutated;
EGF/EGFR genetic polymorphisms
Esophagus cancer EGFR overexpressed and rarely mutated;
EGF/EGFR genetic polymorphisms
Alzheimer’s disease EGFR and ligands overexpressed
Parkinson’s disease EGFR overexpressed in chronic Parkinsonian
syndromes
Alterations in EGFR expression levels can be also observed
during neurodegeneration. Studies performed by Repetto and
co-workers demonstrated that presenilin 1 (PS1) is a critical reg-
ulator of the EGFR pathway (Repetto et al., 2007). Mutations
in PS1 and PS2 genes are responsible for the vast majority of
early onset familial AD (Sherrington et al., 1995). Presenilin
forms an active γ-secretase complex together with Nicastrin
(NCT), APH-1, and PEN-2, which among other substrates cleaves
the beta-amyloid precursor protein (β-APP) generating the Aβ
and the β-APP intracellular domain. The PS1 and PS2 muta-
tions alter the activity of the γ-secretase complex, leading to
changes in the ratio of Aβ, favoring Aβ42 generation and accel-
erated amyloid deposition in brain, the hallmark of AD (De
Strooper, 2007). However, according to Repetto and co-workers,
presenilins may be involved in the modulation of signaling cell
surface receptors that could alter the neuronal viability. They
observed that EGFR levels were robustly increased in fibrob-
lasts deficient in both PS1 and PS2 and the stable transfec-
tion of wild-type PS1 but not PS2 corrected EGFR to levels
comparable to PS+/+ cells (Repetto et al., 2007). Li and co-
workers demonstrated that the levels of EGFR are inversely
correlated with the level of γ-secretase in fibroblasts, suggest-
ing that the up-regulation of EGFR stimulates hyperprolifera-
tion in epithelia of mice with genetic reduction of γ-secretase
(Li et al., 2007). The EGFR pathway seems to have an impor-
tant role in the development of the nervous system, promoting
the growth and differentiation of neural stem cells (Currais
et al., 2009). However, according to Currais and co-workers, the
higher levels of the EGFR specific ligand, EGF, induce neuronal
death, and strong EGFR immunoreactivity has been detected
in neurites surrounding neuritic plaques in AD (Currais et al.,
2009). The loss of PS1 can stimulate the activation of EGFR
and β-catenin pathways, which can contribute to neurodegen-
eration and aberrant cell cycle re-entry (Repetto et al., 2007)
(Table 1).
THE EGFR PATHWAYS AND THE MIR-221/222 EXPRESSION
REGULATION
As a consequence of EGFR signaling activation, the transcription
of several genes and regulators occurs. The EGFR pathway seems
to be involved in the regulation of a panel of miRNAs essential for
metastatic phenotypes and neurodegeneration.
MiRNAs arise from intergenic or intragenic genomic regions
that are transcribed as long primary transcripts. The primary
transcripts then undergo processing steps, which involve Drosha
and Dicer enzymes, to form a mature miRNA (Calin and Croce,
2006). The mature miRNA binds to specific regions of tar-
get mRNA transcripts and destabilizes the target transcript,
blocks its translation, or both. Changes in miRNA expression
can contribute to oncogenesis and neurodegeneration, enhanc-
ing proliferation and leading to genomic instability, causing
increased DNA damage. MiRNAs can be defined as one of the
“guardians” of the genome, maintaining the genomic stability
throughout the life of a cell. Major miRNA expression levels
are detected in the brain; however, their expression patterns
have not yet been fully described. Recent studies identified two
miRNAs, miR-221 and miR-222, as downstream targets of the
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EGFR-RAS-RAF-MEK pathway, by the use of EGFR and MEK
inhibitors, which knocked down the expression of both miRNAs
and Fos-related antigen 1 (FOSL1) (Shah and Calin, 2011; Stinson
et al., 2011).
Studies performed by Kumar and co-workers showed that the
depletion of Dicer from various cancer cell lines increased colony
formation efficiency and augmented tumor burden and aggres-
siveness in vitro (Kumar et al., 2007). In normal adult mouse skin
and embryonic fibroblasts, the Dicer knock-out led to premature
senescence (Shalgi et al., 2009). Dicer depletion can elicit senes-
cence or changes in proliferation of normal or cancer cells, and
can also alter the phosphorylation patterns of tau proteins before
neuronal cell loss, indicating that some mechanisms of neurode-
generation might be controlled by miRNAs (Hebert et al., 2010).
Studies showed the loss of midbrain dopaminergic neurons in
Dicer knock-out mice in the post-mitotic midbrain, which is a
Parkinson’s disease (PD)-like phenotype. These observations sug-
gest that miRNAs are essential for the terminal differentiation
and/or maintenance of multiple neuron types (Srivastava et al.,
2012). Psychiatric and neurological disorders, such as schizophre-
nia, depression, and mental health disorders also appear to be
associated with changes in miRNA expression. For example,
schizophrenia is associated with a global increase in miRNA bio-
genesis and expression in the cerebral cortex, such as the global
increase in expression of miR-26b and miR-30b (Manolis and
Manolis, 2012).
The up-regulation of miR-221/222 has been described in sev-
eral human cancers, including glioblastoma, melanoma, hepato-
cellular carcinoma, kidney and bladder cancers, gastric cancer,
pancreatic cancer, ovarian cancer, and prostate cancer (Negrini
et al., 2009; Coppola et al., 2010). This up-regulation was also
observed in circulation, as free miRNAs, in renal cell carci-
noma patients compared with healthy individuals (Teixeira et al.,
2012). The circulating levels of specific miRNAs are a promising
strategy in the identification of cancer expression profiles predic-
tive of treatment response, which will allow us to individualize
treatments.
MiR-221/222 are also involved in the metastatic process. Their
expression levels are correlated with the repression of transcrip-
tional factors, such as the zinc finger transcription factor Trps1
(TRPS1). The repression of this factor causes an increase in
the levels of the zinc finger E-box-binding homeobox 2 pro-
tein (ZEB2), which promotes a crucial step in the epithelial-to-
mesenchymal transition (EMT), essential for the development of
metastasis (Shah and Calin, 2011).
On the other hand, miR-221/222 seem to be involved in acqui-
sition of resistance to antineoplastic therapies. The knockdown of
miR-221/222 in the LNCaP-Abl cell line restored the response to
the dihydrotestosterone (DHT) and also increased the cell line’s
growth response to androgen treatment, suggesting that miR-
221/222 participate in androgen resistant phenotype behavior
(Sun et al., 2009). Accordingly, Rao and co-workers revealed that
they are also involved in acquisition of the resistance to fulves-
trant, a selective estrogen receptor down-regulator (SERD): the
up-regulation of these miRNAs was essential for cell growth and
cell cycle progression of breast cancer resistant cells (Rao et al.,
2011).
MiR-221/222 seem to have the ability to modulate cell cycle
progression. Miller and co-workers demonstrated that miR-
221/222 can modulate cell cycle progression, by repressing cell
cycle inhibitor proteins p27/Kip1 and p57, facilitating cell pro-
liferation and self-renewal (Miller et al., 2008). The high expres-
sion levels of miR-221/222 in glioma tissue samples have been
associated with aggressiveness and poor overall survival. Their
knockdown decreased the invasion capability and tumor growth
and up-regulated the expression of suppressor gene metallopep-
tidase inhibitor 3 (TIMP3), an inhibitor of matrix metallopro-
teinase (MMPs) (Zhang et al., 2012). In glioblastoma cells, the
overexpression of miR-221/222 promoted premature cell cycle
entry, leading to cell death (Medina et al., 2008). This ability to
modulate the cell cycle could help to explain the role of miR-
221/222 in the pathogenesis of neurodegenerative disorders and
in the apoptotic death of injured neurons. Studies performed by
de las Cuevas et al. demonstrated that lymphoblasts from AD
patients exhibit an enhanced stimulation of proliferation and sur-
vival compared with control individuals (De las Cuevas et al.,
2003; Bartolome et al., 2007). This change in proliferative activ-
ity was associated with a high degree of phosphorylation of Akt
and the downregulation of inhibitors of the G1-S checkpoint
p21 and p27. The ability to control cell cycle has been con-
sidered a critical factor in preventing neurons from entering a
vulnerable high risk state for neurodegeneration mechanisms.
FIGURE 2 | Interaction loop between the EGFR signaling pathway and
miR-221/222 expression in the modulation of cellular processes.
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Recently, it has been shown that the prodeath BCL-2-binding
component 3 (BBC3, also known as PUMA) is one of the targets
of miR-221/222. BBC3 is critical for the death of newly generated
neurons in the adult brain and is also a powerful mediator of neu-
ronal apoptosis after various insults (Harder and Libby, 2011).
In vitro studies performed by Hamada and co-workers observed
that miR-221 decreased the expression of Forkhead box O3a
(Foxo3a) and apoptotic peptidase activating factor 1 (Apaf-1),
both of which are known to be involved in apoptosis in PC12
cells (derived from a pheochromocytoma- rat adrenal medulla).
These results suggest a possible role of this miRNA in neuronal
differentiation, as protection against apoptosis (Hamada et al.,
2012).
In consequence of the inverse correlation of miR-221/222 and
TIMP3 levels, the up-regulation of miR-221/222 is associated
with the expression MMPs. It is accepted that MMPs, especially
MMP3, may contribute to neurodegeneration in vivo by partic-
ipating in neuronal apoptosis and inflammation processes (Kim
and Hwang, 2011). Degradation of the inhibitory protein TIMP3
is associated with an increased expression level ofMMP3 in exper-
imental models. This elevation has been reported in several neu-
rodegenerative disorders, such as PD, AD, white matter damage
in vascular dementia, and ischemic neuronal death (Rosenberg
et al., 2001a,b; Kim and Hwang, 2011) (Figure 2). The expres-
sion of MMP3 can be responsible for the coordination of an
effective, rapid death, and clearance of neurons in normal con-
ditions. However, uncontrolled production of MMP3 may result
in triggering a vicious cycle, attacking neurons that are nearby and
undamaged (Kim and Hwang, 2011).
MiR-221/222 are two important downstream modulators of
the EGFR-RAS-RAF-MEK pathway. This interaction loop can
deregulate cellular homeostasis, revealing that these two miRNAs
are key EGFR pathway-effectors. Due the central role of these
miRNAs in several processes and disorders, they are promising
targets for the development of newmolecular therapies, especially
in cases where the anti-EGFR therapies demonstrate poor benefits
and side effects.
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